Lundbeck
HLUN-B.CO
$7.30
Share price
-1.53%
Change (1 day)
-9.91%
Change (1 year)
Categories
Lundbeck is a Danish pharmaceutical company that produces various pharmaceutical products and has the indications schizophrenia, depression, Parkinson's disease and sleep disorders.
Revenue for Lundbeck (HLUN-B.CO)
Revenue in 2024 (TTM): NZ$5.29 Billion
According to Lundbeck
's latest financial reports the company's current revenue (TTM 
) is NZ$5.37 Billion. an increase over the revenue in the year 2023 that were of NZ$4.58 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Lundbeck from 2009 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 | NZ$5.63 B | 23.06% |
| 2023 | NZ$4.58 B | 12.67% |
| 2022 | NZ$4.06 B | 8.92% |
| 2021 | NZ$3.73 B | -1.79% |
| 2020 | NZ$3.80 B | -1.52% |
| 2019 | NZ$3.86 B | -8.22% |
| 2018 | NZ$4.20 B | 12.22% |
| 2017 | NZ$3.74 B | 11.98% |
| 2016 | NZ$3.34 B | 5.91% |
| 2015 | NZ$3.16 B | 4.68% |
| 2014 | NZ$3.01 B | -8.5% |
| 2013 | NZ$3.29 B | 4.88% |
| 2012 | NZ$3.14 B | -17.23% |
| 2011 | NZ$3.80 B | 12.39% |
| 2010 | NZ$3.38 B | -5.5% |
| 2009 | NZ$3.57 B |